EJMK Ventures LLC Sells 5,952 Shares of Astrazeneca Plc $AZN

EJMK Ventures LLC lowered its position in shares of Astrazeneca Plc (NYSE:AZN) by 64.4% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 3,297 shares of the company’s stock after selling 5,952 shares during the period. EJMK Ventures LLC’s holdings in Astrazeneca were worth $650,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also bought and sold shares of AZN. Triumph Capital Management bought a new position in shares of Astrazeneca in the third quarter worth $25,000. MV Capital Management Inc. purchased a new stake in shares of Astrazeneca in the fourth quarter worth $26,000. Bangor Savings Bank boosted its stake in Astrazeneca by 102.7% during the fourth quarter. Bangor Savings Bank now owns 304 shares of the company’s stock valued at $28,000 after buying an additional 154 shares during the period. Eagle Bay Advisors LLC purchased a new position in Astrazeneca during the fourth quarter worth about $30,000. Finally, YANKCOM Partnership purchased a new position in Astrazeneca during the fourth quarter worth about $31,000. Institutional investors own 20.35% of the company’s stock.

Analyst Ratings Changes

Several research firms have weighed in on AZN. Morgan Stanley reaffirmed an “overweight” rating on shares of Astrazeneca in a report on Wednesday, April 8th. Sanford C. Bernstein reissued a “buy” rating on shares of Astrazeneca in a report on Monday, May 4th. TD Cowen restated a “buy” rating on shares of Astrazeneca in a research report on Wednesday, March 18th. DZ Bank raised shares of Astrazeneca from a “neutral” rating to a “buy” rating in a research note on Wednesday, April 29th. Finally, Jefferies Financial Group reiterated a “buy” rating on shares of Astrazeneca in a research report on Friday, June 26th. Fourteen investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $205.33.

Astrazeneca Trading Down 3.0%

Shares of AZN stock opened at $183.99 on Thursday. The company has a quick ratio of 0.71, a current ratio of 0.91 and a debt-to-equity ratio of 0.52. The business has a 50-day moving average price of $183.91 and a two-hundred day moving average price of $187.58. Astrazeneca Plc has a 12-month low of $137.23 and a 12-month high of $212.71. The firm has a market cap of $285.35 billion, a P/E ratio of 27.63, a price-to-earnings-growth ratio of 1.50 and a beta of 0.24.

Astrazeneca (NYSE:AZN) last posted its quarterly earnings data on Wednesday, April 29th. The company reported $2.58 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.52 by $0.06. The firm had revenue of $15.29 billion during the quarter, compared to analysts’ expectations of $14.93 billion. Astrazeneca had a return on equity of 30.86% and a net margin of 17.19%. Equities analysts anticipate that Astrazeneca Plc will post 10.29 EPS for the current fiscal year.

Astrazeneca News Roundup

Here are the key news stories impacting Astrazeneca this week:

• Positive Sentiment: AstraZeneca’s cancer drug Enhertu won a new EU approval for HER2-positive solid tumors, its sixth EU indication, which could expand sales potential and support future revenue growth. AstraZeneca’s Enhertu Wins EU Nod for HER2-Positive Solid Tumors (Revised)
• Positive Sentiment: Several major brokers reiterated buy ratings on AZN, including Goldman Sachs, Bank of America, and JPMorgan, signaling continued analyst confidence in the stock. Goldman Sachs Reaffirms Buy Rating
• Positive Sentiment: Erste Group raised its FY2026 EPS estimate for AstraZeneca, suggesting expectations for stronger earnings than previously forecast.
• Neutral Sentiment: Zacks highlighted AZN as a strong momentum stock and compared it with Illumina, reinforcing that the shares remain on investors’ radar, but without a direct new catalyst. Here’s Why Astrazeneca (AZN) is a Strong Momentum Stock
• Negative Sentiment: Despite the positive company-specific news, AZN still traded lower as broader market weakness and a conflicting sell rating from Deutsche Bank likely weighed on sentiment. Deutsche Bank Sell Rating

About Astrazeneca

AstraZeneca plc is a global biopharmaceutical company headquartered in Cambridge, England. Formed through the 1999 merger of Sweden’s Astra AB and the UK’s Zeneca Group, the company researches, develops, manufactures and commercializes prescription medicines across a range of therapeutic areas. AstraZeneca positions itself as R&D-driven, investing in discovery science, clinical development and regulatory processes to bring new therapies to market.

The company’s commercial portfolio and late-stage pipeline emphasize oncology, cardiovascular, renal and metabolic (CVRM) diseases, and respiratory and immunology.